[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343861-105":59,"doc-detail-343861-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-prmt5-through-protac-for-the-treatment-of-triple-negative-breast-cancer","Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer","","Triple-negative breast cancer (TNBC) remains the most aggressive breast cancer subtype, marked by high heterogeneity and strong invasiveness, with limited effective therapies. PRMT5, a type II protein arginine methyltransferase upregulated across cancers including TNBC, is highlighted as an attractive therapeutic target. PROTAC technology enables ubiquitin-proteasome system–mediated degradation, aiming for higher activity, improved safety, reduced resistance, and lower toxicity to support clinical translation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-prmt5-through-protac-for-the-treatment-of-triple-negative-breast-cancer/343861/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-prmt5-through-protac-for-the-treatment-of-triple-negative-breast-cancer/343861.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in triple-negative breast cancer?","Question",{"text":112,"@type":113},"TNBC is aggressive, heterogeneous, and invasive, and currently lacks effective targeted therapies. The paper frames PRMT5 as a therapeutic vulnerability to address this gap.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the study approach targeting PRMT5?",{"text":117,"@type":113},"The research uses PROTAC technology to develop PRMT5-directed degraders and evaluates them in vitro and in vivo.",{"name":119,"@type":110,"acceptedAnswer":120},"What key results were reported for the lead compound?",{"text":121,"@type":113},"The study identifies YZ-836P, which reduces PRMT5 and downstream KLF5 protein levels in TNBC cells and shows strong anti-tumor activity in patient-derived organoids and xenografts, with effects mediated via CRBN-dependent ubiquitination and degradation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343861,1790167443,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Guo et al. Journal of Experimental & Clinical Cancer Research (2024) 43:314 [https://doi.org/10.1186/s13046-024-03237-y](https://doi.org/10.1186/s13046-024-03237-y)  \nJournal of Experimental & Clinical Cancer Research  \nRESEARCH Open Access  \nTargeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer  \nYaxun Guo 1†, Yuzhan Li2†, Zhongmei Zhou3, Lei Hou4, Wenjing Liu5, Wenlong Ren6,7, Dazhao Mi2, Jian Sun5, Xueqin Dai8, Yingying Wu9, Zhuo Cheng7, Tingyue Wu7, Qianmei Luo7, Cong Tian4, Fubing Li8*, Zhigang Yu 1,10,11*, Yihua Chen2,12,13* and Ceshi Chen5,8*  \nAbstract  \nBackground Triple-negative breast cancer (TNBC) is currently the most aggressive subtype of breast cancer, characterized by high heterogeneity and strong invasiveness, and currently lacks effective therapies. PRMT5, a  \ntype II protein arginine methyltransferase, is upregulated in numerous cancers, including TNBC, and plays a critical role, marked it as an attractive therapeutic target. PROTAC (Proteolysis Targeting Chimeras) is an innovative drug development technology that utilizes the ubiquitin-proteasome system (UPS) to degrade target proteins, which is characterized by higher activity, enhanced safety, lower resistance, and reduced toxicity, offering significant value for clinical translation.  \nMethods This study utilizes the PROTAC technology to develop potential degraders targeting PRMT5 in vitro and in vivo.  \nResults Through the design, synthesis and screening of a series of targeted compounds, we identified YZ-836P as an effective compound that exerted cytotoxic effects and reduced the protein levels of PRMT5 and its key downstream target protein KLF5 inTNBC after 48 h. Its efficacy was significantly superior to the PRMT5 PROTAC degraders that had been reported. YZ-836P induced G1 phase cell cycle arrest and significantly induced apoptosis inTNBC cells. Additionally, we demonstrated that YZ-836P promoted the ubiquitination and degradation of PRMT5 in a cereblon (CRBN)-dependent manner. Notably, YZ-836P exhibited pronounced efficacy in inhibiting the growth ofTNBC patientderived organoids and xenografts in nude mice.  \nConclusions These findings position YZ-836P as a promising candidate for advancing treatment modalities forTNBC. Trial registration Ethics Committee of Yunnan Cancer Hospital, KYCS2023-078 . Registered 7 June 2023.  \n†Yaxun Guo andYuzhan Li contributed equally to this work.  \n*Correspondence:  \nFubing Li[mtlfb0408@163.com](mtlfb0408@163.com)[ ](mtlfb0408@163.com)Zhigang Yu[yuzhigang@sdu.edu.cn](yuzhigang@sdu.edu.cn)[ ](yuzhigang@sdu.edu.cn)Yihua Chen[chenyihua@kmmu.edu.cn](chenyihua@kmmu.edu.cn)[ ](chenyihua@kmmu.edu.cn)Ceshi Chen[chenc@kmmu.edu.cn](chenc@kmmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nGuo et al. Journal of Exper","cbCaibD9kwCwQEqG","https://ap.wps.com/l/cbCaibD9kwCwQEqG","pdf",2777723,15,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background","[{\"question\":\"What problem does the study address in triple-negative breast cancer?\",\"answer\":\"TNBC is aggressive, heterogeneous, and invasive, and currently lacks effective targeted therapies. The paper frames PRMT5 as a therapeutic vulnerability to address this gap.\"},{\"question\":\"How does the study approach targeting PRMT5?\",\"answer\":\"The research uses PROTAC technology to develop PRMT5-directed degraders and evaluates them in vitro and in vivo.\"},{\"question\":\"What key results were reported for the lead compound?\",\"answer\":\"The study identifies YZ-836P, which reduces PRMT5 and downstream KLF5 protein levels in TNBC cells and shows strong anti-tumor activity in patient-derived organoids and xenografts, with effects mediated via CRBN-dependent ubiquitination and degradation.\"}]","Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer | PDF",1790052332,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d583f475423547670657ed85fcb99d4.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ad9a24a0875ac76a8beb6dc0a58fc70.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4567f683e10a884ffda934c31a79240.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e636ec0d48295da64a58e39aa6eb5a7.webp",980,1306]